Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

A -- Accelerated Manufacturing of Pharmaceuticals Teaming and Information Session

Active
SN06-26Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The Defense Advanced Research Projects Agency (DARPA) Defense Sciences Office (DSO) is hosting a teaming and information session for its Accelerated Manufacturing of Pharmaceuticals (AMP) program, which aims to develop a rapid, flexible, and cost-effective manufacturing system capable of producing three million doses of GMP-quality vaccines or monoclonal antibodies within 12 weeks. The session is scheduled for May 26, 2006, at Strategic Analysis, Inc. in Arlington, VA, with a registration deadline of May 19, 2006. This event is designed to introduce the research community, including industry, academia, and government entities, to the program’s vision and goals and to foster the formation of multidisciplinary teams with the expertise and facilities required to meet the program’s objectives and milestones. The session will feature presentations from DARPA and FDA personnel and encourage attendees to submit posters highlighting their capabilities to facilitate collaboration, with a maximum of 100 posters accommodated. Attendance is limited to 100 people and capped at two members per group; registration is free but required due to space constraints. Additional information and registration details are available through the designated teaming website, which also serves as a platform for team-building activities. The event is not a request for proposals but serves as a resource for potential participants in response to the related BAA06-31 solicitation. Points of contact for technical and administrative inquiries are provided to support interested parties in preparing to engage with the AMP program effectively.

General Info

DARPA hosts May 26 session for AMP vaccine manufacturing, fostering multidisciplinary team formation.

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Place of Performance

VA

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

Posted

special-notice

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Defense Advanced Research Projects Agcy
Contacts1 person available
OfficeARLINGTON, VA, 222032114, USA
Office AddressARLINGTON, VA, 222032114, USA
Contacts
Michael G CallahanDSO Program Manager

Full Description

Show more
Special Notice SN 06-26: Accelerated Manufacturing of Pharmaceuticals Teaming and Information Session DATE: May 26, 2006, REGISTRATION DEADLINE: May 19, 2006, TECHNICAL POC: Dr. Michael Callahan, DARPA/DSO, Ph: (571) 218-4537, URL: http://www.sainc.com/ampteaming/ Accelerated Manufacturing of Pharmaceuticals (AMP), SN06-26. The Defense Sciences Office (DSO) of the Defense Advanced Research Projects Agency (DARPA) is sponsoring a teaming and information session for AMP, a new DARPA program. The vision of the Accelerated Manufacturing of Pharmaceuticals (AMP) program is to create an extremely rapid, flexible and cost-effective manufacturing system capable of producing three million doses of GMP-quality vaccines or monoclonal antibodies (mAB) within 12 weeks. A highly integrated, multi-disciplinary team capable of fulfilling the entire vision, meeting all program objectives and milestones for each phase of the program is strongly encouraged. The teaming and information session will be held at Strategic Analysis, Inc., Executive Conference Center 3601 Wilson Blvd. Arlington, VA, on May 26, 2006. The goals of the teaming and information session are: (a) introduce the research community (industry, academia, and Government) to the AMP program vision and goals; and (b) encourage and promote teaming arrangements among potential research organizations that have the relevant expertise, facilities, and capabilities for executing a research and development program responsive to the AMP program goals. The teaming and information session will include overview presentations by Government personnel including personnel from DARPA and the FDA. Additionally, a teaming website is provided to facilitate teaming interactions and can be found at http://www.sainc.com/ampteaming/. We encourage all teams to register and post on the AMP Teaming Website. Appropriate teaming will be a critical element in responding to the DARPA AMP BAA06-31. Teaming and information session participants are strongly encouraged to prepare posters describing areas of capabilities in order to facilitate communications, interactions, and teaming discussions during the poster session. Posters must be submitted through the teaming website by May 19, 2006, at 4 P.M. ET. A maximum of 100 4ft. by 4 ft. posters can be accommodated. Teaming and information session details (including registration information and poster submissions) will be available on the AMP Teaming website at http://www.sainc.com/ampteaming/. There is no fee for any teaming and information session activities. Registration is limited by the venue capacity (maximum of 100 attendees). As a result of venue capacity, the session is limited to a maximum of two members per group. Early registration is strongly recommended. The registration cutoff date is May 19, 2006, at noon ET, or at attendance capacity, whichever comes first. Further administrative information is available from Tina Orr (torr@sysplan.com). Additional technical information can be obtained from Michael Callahan (michael.callahan@darpa.mil). Please refer to the - AMP Teaming and Information Session in correspondence. This announcement is not a request for proposals. The solicitation document is available at http://www.darpa.mil/baa/baa06-31.html. Material presented at the teaming and information session, including posters presented at the poster session DARPA presentations, and any DARPA response to clarification inquiries, will also be available at http://www.sainc.com/ampteaming/ for those interested in BAA06-31 but unable to attend. Original Point of Contact Michael Callahan, DARPA Program Manager, Phone (571) 218-4537 Teaming Website: http://www.sainc.com/ampteaming/.

Similar Contracts

Same NAICS industry code

More opportunities from Department Of Defense → Defense Advanced Research Projects Agcy

Same awarding agency

NAICS: 541714
New
Federal
Pre-Award Synopsis Texas Shield
Solicitation # DARPA-SN-27-07
The Defense Advanced Research Projects Agency (DARPA), through its Biological Technologies Office (BTO), intends to enter into an agreement with The University of Texas System consortium of universities for the Texas Shield Program. This integrated research initiative, identified by solicitation number DARPA-SN-27-07 and NAICS code 541714, focuses on developing autonomous and semi-autonomous medical technologies and scalable solutions for critical medical consumables. The primary goal is to support lifesaving medical care in contested, austere, and resource-limited environments. Key technical areas of focus include autonomous medical and robotic surgical systems, casualty evacuation, artificial-blood and supply innovation, AI-enabled clinical decision support, and mass-casualty science and simulation. This notice is a pre-award synopsis and is not a request for proposals or a competitive solicitation. Interested entities are invited to submit information by November 15, 2026, to TexasShieldxBTO@darpa.mil detailing their technical expertise, integrated research infrastructure, clinical-validation capabilities, and multi-institutional coordination capacity. Additionally, respondents must describe their consortium organizational structure, commercialization capabilities, facility clearance levels, and their ability to handle Controlled Unclassified Information. The government will not reimburse any costs associated with the preparation or submission of information in response to this notice.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

4 days ago

DEADLINE

in 26 days
View Details
NAICS: 541715
New
Federal
Intrinsic Market Resilience (IMR)
Solicitation # DARPA-PS-26-138
The Intrinsic Market Resilience (IMR) program, solicited by the DARPA Information Processing Techniques Office under DARPA-PS-26-138, is a 32-month initiative spanning Fiscal Years 2027 through 2029. The program aims to protect essential U.S. economic sectors from systemic risks and adversarial attacks targeting the public interfaces of modern electronic markets. By combining Large Language Model (LLM) automation with rigorous mathematical modeling, IMR seeks to develop tools that automatically translate informal regulatory and technical specifications into formal models to identify hidden weaknesses and recommend structural repairs. The work is divided into three technical areas: TA1 focuses on modeling and analysis, TA2 on resiliency and repair, and TA3 on establishing test and evaluation frameworks to validate the outputs of the first two areas. This procurement is conducted as an Other Transaction (OT) for Prototype Agreement under 10 U.S.C. 4022, with anticipated award ranges of 4.5 to 5 million dollars for TA1, 2.5 to 3 million dollars for TA2, and 5 to 6.5 million dollars for TA3. Eligible participants include small businesses, nonprofit research institutions, and nontraditional defense contractors. Proposers must adhere to strict security requirements, including CMMC Level 1 compliance at award and CMMC Level 2 status or a detailed compliance plan. All information must be handled according to NIST 800-171 and DFARS 252.204-7012 standards. Evaluation is based on technical approach, qualifications, technology transition viability, price, and security, with a particular emphasis on innovation and the feasibility of the proposed technical solution.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

4 days ago

DEADLINE

in about 2 months
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS